DWTX

+ Watchlist + Portfolio

Dogwood Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.31
52-Week Range: $1.28 – $9.50
Market Cap: $79.20M
P/E (TTM): 1.23
EPS (TTM): 1.89
Dividend Yield: —

Advanced Metrics

Price/Book: 0.93
PEG Ratio: —
Return on Equity: -47.77%
Return on Assets: -20.83%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 3.89
Debt/Equity: 0.00
Total Debt: $127.21K
Free Cash Flow: $-16.36M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $69.38M

DWTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$8.07M	$1.73M	$3.53M	$21.87M
Selling, General & Admin	$4.25M	$3.72M	$8.70M	$6.10M
Operating Expenses	$12.32M	$5.45M	$12.23M	$27.97M
Operating Income	-$12.32M	-$5.45M	-$12.23M	-$27.97M
EBITDA	-$12.32M	-$5.45M	-$12.22M	-$27.97M
Pretax Income	-$12.25M	-$5.30M	-$12.35M	-$34.04M
Income Tax	$0.00	$0.00	-$503.00	$221.10K
Net Income	-$12.25M	-$5.30M	-$12.35M	-$34.26M
Diluted EPS	-27.75	-7.00	-12.52	-7.13
Diluted Shares	442804	751071	1.03M	4.98M

DWTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$7.03M	$3.32M	$14.85M	$6.52M
Current Assets	$8.37M	$4.17M	$16.54M	$8.43M
Total Assets	$8.37M	$4.17M	$94.31M	$90.17M
Current Liabilities	$1.04M	$358.55K	$3.18M	$3.06M
Long-Term Debt	—	—	$15.38M	—
Total Debt	—	$0.00	$15.59M	$162.60K
Total Liabilities	$1.04M	$358.55K	$30.03M	$15.27M
Retained Earnings	-$56.17M	-$61.47M	-$73.82M	-$108.08M
Shareholders' Equity	$7.33M	$3.81M	$64.28M	$74.90M
Working Capital	$7.33M	$3.81M	$13.37M	$5.37M
Net Debt	—	—	$533.13K	—

DWTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$11.47M	-$4.87M	-$8.79M	-$15.62M
Free Cash Flow	-$11.47M	-$4.87M	-$8.79M	-$15.62M
Depreciation & Amortisation	—	$0.00	$12.18K	$2.06K
Stock-Based Compensation	$582.66K	$619.97K	$476.02K	$355.64K
Investing Cash Flow	—	$0.00	$3.76M	$0.00
Financing Cash Flow	$4.49M	$1.16M	$16.70M	$7.28M
Share Repurchases	—	$0.00	-$351.00	$0.00
Net Change in Cash	-$6.98M	-$3.71M	$11.68M	-$8.33M

DWTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.44M	$2.57M	$14.52M	$2.34M	$2.67M
Selling, General & Admin	$1.99M	$1.35M	$1.29M	$1.47M	$2.41M
Operating Expenses	$4.43M	$3.92M	$15.81M	$3.81M	$5.08M
Operating Income	-$4.43M	-$3.92M	-$15.81M	-$3.81M	-$5.08M
EBITDA	-$4.41M	-$3.91M	-$15.81M	-$3.81M	-$5.08M
Pretax Income	-$10.73M	-$3.81M	-$15.75M	-$3.75M	-$4.99M
Income Tax	$190.54K	$149.00	-$1.44K	$31.84K	$1.19K
Net Income	-$10.92M	-$3.81M	-$15.74M	-$3.78M	-$4.99M
Diluted EPS	-8.45	-1.99	-8.20	-0.26	-0.15
Diluted Shares	1.44M	1.91M	1.92M	14.52M	33.54M

DWTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$17.54M	$13.40M	$10.13M	$6.52M	$13.23M
Current Assets	$19.16M	$14.70M	$11.66M	$8.43M	$15.00M
Total Assets	$96.98M	$96.69M	$91.99M	$90.17M	$95.21M
Current Liabilities	$2.58M	$1.89M	$2.60M	$3.06M	$2.56M
Total Debt	$191.24K	$186.99K	$174.78K	$162.60K	$144.93K
Total Liabilities	$14.24M	$14.15M	$14.61M	$15.27M	$14.58M
Retained Earnings	-$84.74M	-$88.55M	-$104.30M	-$108.08M	-$113.06M
Shareholders' Equity	$82.75M	$82.54M	$77.39M	$74.90M	$80.62M
Working Capital	$16.58M	$12.82M	$9.06M	$5.37M	$12.44M

DWTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.68M	-$4.03M	-$3.27M	-$3.64M	-$4.59M
Free Cash Flow	-$4.68M	-$4.03M	-$3.27M	-$3.64M	-$4.59M
Depreciation & Amortisation	$17.02K	$17.26K	-$32.22K	$0.00	$0.00
Stock-Based Compensation	$84.47K	$65.03K	$48.28K	$157.86K	$449.42K
Financing Cash Flow	$7.37M	-$120.13K	$0.00	$32.56K	$11.29M
Net Change in Cash	$2.69M	-$4.15M	-$3.27M	-$3.60M	$6.70M

Market Snapshot

About

Dogwood Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious diseases with significant unmet medical needs. The company's pipeline includes novel therapeutic candidates targeting various conditions, with a focus on precision medicine approaches. As a development-stage company, Dogwood is advancing its drug candidates through clinical trials and regulatory processes. The company does not yet have any commercialized products and generates no product revenue.